JANX
Companies
NASDAQ
Janux Therapeutics Inc.
Health Care
$22.72
-$29.95 (-55.94%)
Price Chart
Overview
About JANX
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Market Cap
$2.3B
Volume
29.2M
Avg. Volume
25.1M
P/E Ratio
-14.943749
Dividend Yield
0.00%
Employees
36.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.27
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, JANX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.3B
Volume29.2M
P/E Ratio-14.94
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025